<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0003674'>Oxidative stress</z:mp> is implicated in the pathogenesis of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion injury </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, we demonstrated that activation of CD36, a class B scavenger receptor, mediates free radical production and tissue injury in <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> (1) </plain></SENT>
<SENT sid="2" pm="."><plain>Oxidized <z:chebi fb="2" ids="39026">low density lipoproteins</z:chebi> (oxLDL) are among the ligands that bind to CD36 and are elevated in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>SS31 is a cell-permeable <z:chebi fb="11" ids="22586">antioxidant</z:chebi> <z:chebi fb="7" ids="16670">peptide</z:chebi> that reduces intracellular free radicals and inhibits <z:chebi fb="15" ids="39026">LDL</z:chebi> oxidation/<z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation (2) </plain></SENT>
<SENT sid="4" pm="."><plain>The current study was designed to investigate whether treatment with SS31 normalizes <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced redox changes and attenuates CD36-mediated tissue injury </plain></SENT>
<SENT sid="5" pm="."><plain>C57BL/6 mice were subjected to transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="6" pm="."><plain>Redox status and <z:mpath ids='MPATH_124'>infarct</z:mpath> volume were measured in animals treated with either saline or SS31 </plain></SENT>
<SENT sid="7" pm="."><plain><z:mp ids='MP_0003674'>Oxidative stress</z:mp> induced by <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion profoundly depleted <z:chebi fb="0" ids="16856">glutathione</z:chebi> (GSH) concentrations in the ipsilateral cortex and striatum </plain></SENT>
<SENT sid="8" pm="."><plain>Treating mice with SS31 immediately after reperfusion significantly attenuated <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced GSH <z:mpath ids='MPATH_63'>depletion</z:mpath> in the cortex and reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> size </plain></SENT>
<SENT sid="9" pm="."><plain>By contrast, the protective effect of SS31 was absent in CD36 knock-out mice, indicating that SS31 is acting through inhibition of CD36 </plain></SENT>
<SENT sid="10" pm="."><plain>Treating C57BL/6 mice with SS31 reduced CD36 expression in postischemic brain and mouse peritoneal macrophages (MPM) </plain></SENT>
<SENT sid="11" pm="."><plain>Further in vitro studies revealed that SS31 attenuated oxLDL-induced CD36 expression and foam cell formation in MPM </plain></SENT>
<SENT sid="12" pm="."><plain>These in vivo and in vitro studies indicate that the down-regulation of CD36 by novel class <z:chebi fb="11" ids="22586">antioxidant</z:chebi> <z:chebi fb="7" ids="16670">peptides</z:chebi> may be a useful strategy to treat <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> victims </plain></SENT>
</text></document>